0
0
CHANDIGARH — In a potential paradigm shift for pain management, researchers at the Post Graduate Institute of Medical Education and Research (PGIMER) have unveiled a pioneering PET-CT-guided therapy designed to pinpoint and treat the “true” source of chronic musculoskeletal pain. By utilizing advanced molecular imaging to guide a robotic-assisted injection, the clinical team reported a significant 84% success rate in reducing pain for patients who had previously failed conventional treatments. The breakthrough, described as a world-first, addresses a long-standing frustration in medicine: the often-blurry link between what an X-ray shows and where a patient actually hurts.
The “Invisible” Source of Pain
For millions living with chronic back, neck, or joint pain, the diagnostic process can feel like a guessing game. Standard imaging tools like MRIs and X-rays are excellent at showing structural changes—such as a worn-down disc or a bone spur—but these findings are frequently “false positives.” Many people with visible structural damage feel no pain, while others with “clean” scans suffer daily.
“The gap between structural changes and clinical symptoms has frustrated both patients and clinicians for decades,” says Dr. Anish Bhattacharya, Head of Nuclear Medicine at PGIMER.
To bridge this gap, the PGIMER team turned to [18F] sodium fluoride (NaF) PET-CT. Unlike traditional scans that only show the “hardware” of the body, this molecular imaging tracks metabolic activity. It highlights “hot spots” where bone and tissue are undergoing rapid, abnormal turnover—often the smoking gun for active inflammation and pain.
Precision Delivery via Robotic Assistance
The new protocol doesn’t just find the pain; it delivers the treatment with surgical accuracy. Once the NaF PET-CT identifies a metabolically active site, such as a specific facet joint in the spine, a robotic-arm-assisted system guides a needle to the exact coordinate to deliver a targeted steroid injection.
In a single-arm Phase 2 study recently published in the European Journal of Nuclear Medicine and Molecular Imaging, the results were promising:
-
Success Rate: 84% of participants reported significant pain relief at the three-month mark.
-
Safety: No major complications or adverse events were reported.
-
Conditions Treated: The technique was applied to lumbar facet joint arthropathy, sacroiliitis (inflammation of the lower spine joints), plantar fasciitis, and coccydynia (tailbone pain).
“This innovation has the potential to transform chronic pain management globally,” stated Prof. Vivek Lal, Director of PGIMER, noting that the procedure remains accessible, costing approximately ₹1,500 (roughly $18 USD) at the institute.
A Global Crisis of Disability
The timing of this breakthrough is critical. According to the World Health Organization (WHO), low back pain is the leading cause of disability worldwide, affecting an estimated 619 million people as of 2020. That number is projected to climb to 843 million by 2050.
In the United States, the Centers for Disease Control and Prevention (CDC) reports that chronic pain affects nearly 21% of the adult population. For these individuals, the “trial-and-error” nature of pain management—switching between physical therapy, various medications, and generalized injections—can lead to psychological distress and opioid dependency.
Expert Perspectives: A Grain of Salt
While the PGI team is optimistic, independent experts urge a balanced interpretation of the data. Because the study was “single-arm”—meaning every participant received the treatment and there was no “control group” receiving a placebo—it is difficult to determine how much of the 84% success rate was due to the “placebo effect” or the natural wax and wane of chronic pain.
“The use of NaF PET-CT is an elegant way to identify active biology,” says one independent pain specialist not involved in the study. “However, earlier randomized trials have occasionally shown a mismatch where high tracer uptake didn’t always correlate with the intensity of a patient’s pain. We need larger, randomized controlled trials to prove this is truly superior to standard ultrasound or CT-guided injections.”
Limitations and Considerations
Patients considering such advanced imaging must weigh several factors:
-
Radiation Exposure: A PET-CT scan involves more radiation than a standard X-ray or MRI.
-
Selection Bias: The PGI study focused on patients who already showed “NaF-avid” lesions (clear hot spots on the scan). It may not work for patients whose pain is purely nerve-based or systemic.
-
Availability: While cost-effective at PGI Chandigarh, PET-CT technology is expensive and primarily available only at major tertiary hospitals or specialized imaging centers.
What This Means for You
If you are struggling with chronic pain that hasn’t responded to traditional care, the PGI breakthrough offers two major takeaways:
-
The “Pain Generator” Matters: If standard injections haven’t worked, it may be because the needle didn’t hit the true metabolic source of the pain.
-
Don’t Chase the Scan: A standard MRI should not be the “final word” on your condition. Comprehensive evaluations should include your physical history and, potentially, functional imaging like PET-CT if symptoms persist.
As medicine moves toward “precision care,” the goal is to stop treating the symptoms and start treating the specific biological driver. PGIMER’s work is a significant step toward a future where “where it hurts” is answered by science, not just guesswork.
Reference Section
- https://medicaldialogues.in/news/health/hospital-diagnostics/pgi-chandigarh-unveils-worlds-first-pet-ct-guided-therapy-for-chronic-pain-management-168736
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
